HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

31
HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

description

HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University. Drug Terminology Efforts in HL7. Need for medication terms Much source data generated by pharmacy systems Pharmacy knowledge base vendors are exploring ways to place their terminologies in the public domain - PowerPoint PPT Presentation

Transcript of HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Page 1: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

HL7 Drug Name Coordination Efforts

James J. Cimino, M.D.Columbia University

Page 2: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Drug Terminology Efforts in HL7

• Need for medication terms

• Much source data generated by pharmacy systems

• Pharmacy knowledge base vendors are exploring ways to place their terminologies in the public domain

• Vocabulary TC convened meetings to explore ways of collaborating

Page 3: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Disclaimer

• Nothing is a balloted standard yet

• TC has not yet proposed a formal model

• TC has not yet proposed a plan of action

• TC is still defining scope and goals

Page 4: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Drug Terminology Modeling

• Some agreement on the concept of a "clinical drug"

• More-specific terms

• Less-specific terms

• Dosage forms

• Routes

Page 5: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Clinical Drugs

• Active ingredients

• Dosage form

Page 6: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Trademark Drugs

• Trademark

• Active ingredients

• Dosage form

Page 7: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Manufactured Components

• Inactive ingredients

• Dispensing and Inventory

• Manufacturer (may not be the same as supplier)

• Active ingredients

• Dosage form

• Trademark

Page 8: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Drug Model Hierarchy

Drug Class

Not-Fully-Specified Drug

Clinical Drug

Trademark Drug

Manufactured Components

Ingredient Class

International Package Identifiers

Country-Specific Packaged Product

Ingredient

is-a

is-a

is-a

is-a

is-a

is-a

Chemicals

MedicationsPackages

Composite Clinical Drug

is-a

Composite Trademark Drug

is-a

Page 9: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Drug Model Hierarchy

Drug Class

Not-Fully-Specified Drug

Trademark Drug

Manufactured Components

Ingredient Class

International Package Identifiers

Country-Specific Packaged Product

Ingredient

is-a

is-a

is-a

is-a

is-a

is-a

Chemicals

MedicationsPackages

Composite Clinical Drug

is-a

Composite Trademark Drug

is-a

Clinical Drug

Page 10: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Clinical Drugs

• Dosage form

• Active ingredients– Chemical

– Form Strength• Strength amount

• Strength units

• Volume

• Volume units

Page 11: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Experiment

• Can model allow for interoperability?– Single terminology vs.– Mapping between terminologies

• Select random sample of drug terms

• Obtain descriptions from terminology developers

• Compare description components

• Examine overall match rate

Page 12: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Sample Selection

• 71,000 NDC Codes

• 1000 selected at random (1.4%)

• Many are obsolete

Page 13: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Descriptions from Vendors

Name Form Ingredient 1 Ingredient 2

Valium 5mg Tablet Tablet Diazepam ^5^mg

Tylenol #3 Tablet Acetaminophen Codeine ^325^mg ^30^mg

Chloral Hydrate Syrup Syrup Chloral Hydrate 100.000000^mg^1.000000^ml

Page 14: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Descriptions from Vendors

Set Mapped

A 358

B 459

C 605

D 405

E 566

A B C D E None

- 340 358 326 357 642

340 - 452 361 449 541

358 452 - 393 554 395

326 361 393 - 392 395

357 449 554 392 - 434

Overall, 367 terms were not represented in any set, 71 appeared in only one set, 77 appeared in exactly two sets, 83 appeared in three sets, 91 appeared in four, and 311 terms appeared in all five terminologies.

Page 15: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Pairwise Comparisons

Set B C D E

A 340 358 326 357

B 452 361 449

C 393 554

D 392

E

Page 16: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Pairwise Comparisons

Set B C D E

A 340 358 326 357

B 452 361 449

C 393 554

D 392

E

{3982

Page 17: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Comparisons

• Dosage Form: 3982

• Ingredient (number and match): 5507

• Dose Strength (dose, units, volume, volume units): 4337

• Overall: 3982

Page 18: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Dosage Form Matching

• TAB = TABLET

• LIQUID ORAL LIQUID

• 111 Dosage form synonyms

Page 19: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Ingredient Matching

• HCl vs. Hydrochloride

• Salt vs. Base

• Inclusion of form or route

• Mention of animal source

Page 20: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Matching Other Components

• Dose Strength Matching

• Dose Units Matching

• Dose Volume Matching

• Dose Volume Units Matching

Page 21: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Overall Matching

• Form matches

• Same number of ingredients

• Each ingredient matches on chemical and all four other parameters

Page 22: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Overall Matching

Total Before After Conversion Conversion Components: Ingredients 5507 3607 (65%) 4337 (79%) Strength 4337 374 (9%) 3262 (75%) Units 4337 1845 (43%) 2964 (68%) Volume 4337 1054 (24%) 3754 (87%) Volume Units 4337 2319 (53%) 3486 (80%)

Components:

Overall: Each Ingred 4337 0 (0%) 2773 (64%) All Ingred 3982 0 (0%) 2519 (63%) Dose Form 3982 645 (16%) 2859 (72%) Complete Drug 3982 0 (0%) 2128 (53%)53%

Page 23: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Pairwise Comparisons

Set A B C D E

A - 340 358 326 357

B 340 - 452 361 449

C 358 452 - 393 554

D 326 361 393 - 392

E 357 449 554 392 -

Page 24: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Set A B C D E

A - 59% 45% 48% 52%

B 59% - 54% 63% 62%

C 45% 54% - 46% 48%

D 48% 63% 46% - 58%

E 52% 62% 48% 58% -

Pairwise Complete Matches

Page 25: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Example of MismatchGUAIFENESIN AC LIQUID|10;100|MG/5ML;MG/|LIQUID

SYRUP|GUAIFENESIN^00000000.000^^0000.000^CODEINE PHOSPHATE^.^^.^

LIQUID|CODEINE PHOSPHATE^2.000000^MG^^GUAIFENESIN^20.000000^MG^1.000000^ML

LIQUID, ORAL (SYSTEMIC)|CODEINE PHOSPHATE^10^MG^5^MLGUAIFENESIN^100^MG^5^ML

LIQUID|CODEINE PHOSPHATE^10.0000^MG/5ML^^GUAIFENESIN^100.0000^MG/5ML^^

SYRUP|CODEINE PHOSPHATE^10^MILLIGRAM(S)^5^MILLILITER(S)GUAIFENESIN^100^MILLIGRAM(S)^5^MILLILITER(S)

Page 26: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Example of Mismatch

RECOMBIVAX HB ADULT FORMULATION INJECTION|10|MCG|INJ-SUS

HEPATITIS B VIRUS VACCINE

HEPATITIS B SURFACE ANTIGEN

HEPATITIS B VACCINE-RECOMBINANT

HEPATITIS B VIRUS VACCINE RECOMBINANT

HEPATITIS B VACCINE RECOMBINANT

Page 27: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Discussion

• Matching is still far from perfect

• Not surprising, given lack of standards for attribute values

• Next steps

Page 28: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Discussion: Next Steps

• Define some rules for each field

• Select new random sample

• Find subset with good overlap across terminologies

• Submit descriptions of new subset

Page 29: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Discussion: New Rules

• Dose forms: separate translation step• Ingredients:

– Right number– Specific chemical entity– Identifiers (UMLS?)– Don’t mix in route or concentration

• Strengths:– Conversion algorithms– Rules for defaults– Don’t mix route or concentration with strength

Page 30: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University

Conclusions

• Glass half empty:– How can we do automated translation of patient

data?– Can drug order transfers and decision support

be safe?

• Glass half full:– No attempt yet to standardize attribute

terminology– Most translation was much better than 50%– Just getting started– Better than what we do now

Page 31: HL7 Drug Name Coordination Efforts James J. Cimino, M.D. Columbia University